Rakuten Securities Inc. Has $742,000 Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Rakuten Securities Inc. lifted its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 248.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 26,160 shares of the company's stock after buying an additional 18,661 shares during the period. Rakuten Securities Inc.'s holdings in Moderna were worth $742,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Deutsche Bank AG lifted its stake in shares of Moderna by 54.7% in the fourth quarter. Deutsche Bank AG now owns 1,894,075 shares of the company's stock valued at $78,756,000 after buying an additional 669,614 shares during the period. Tang Capital Management LLC bought a new position in Moderna during the fourth quarter worth about $12,474,000. Proficio Capital Partners LLC lifted its stake in Moderna by 4,418.9% during the fourth quarter. Proficio Capital Partners LLC now owns 147,360 shares of the company's stock worth $6,127,000 after purchasing an additional 144,099 shares during the period. South Dakota Investment Council lifted its stake in Moderna by 4.0% during the fourth quarter. South Dakota Investment Council now owns 299,399 shares of the company's stock worth $12,449,000 after purchasing an additional 11,500 shares during the period. Finally, BDF Gestion bought a new position in Moderna during the first quarter worth about $783,000. Institutional investors own 75.33% of the company's stock.

Moderna Trading Down 0.6%

Shares of Moderna stock traded down $0.15 during midday trading on Thursday, reaching $25.40. The company had a trading volume of 7,517,553 shares, compared to its average volume of 8,450,893. The company has a market capitalization of $9.82 billion, a price-to-earnings ratio of -2.91 and a beta of 1.86. The stock has a fifty day simple moving average of $26.27 and a 200 day simple moving average of $32.69. Moderna, Inc. has a 1-year low of $23.15 and a 1-year high of $138.07.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share for the quarter, beating analysts' consensus estimates of ($2.92) by $0.40. Moderna had a negative net margin of 105.67% and a negative return on equity of 28.69%. The business had revenue of $108.00 million during the quarter, compared to analyst estimates of $130.35 million. During the same quarter last year, the business posted ($3.07) earnings per share. Moderna's revenue for the quarter was down 35.3% compared to the same quarter last year. Sell-side analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have commented on MRNA shares. Morgan Stanley cut their price target on shares of Moderna from $39.00 to $32.00 and set an "equal weight" rating for the company in a research note on Wednesday, April 9th. Barclays cut their price target on shares of Moderna from $45.00 to $40.00 and set an "equal weight" rating for the company in a research note on Friday, May 2nd. William Blair restated a "market perform" rating on shares of Moderna in a research note on Monday, June 2nd. UBS Group cut their price target on shares of Moderna from $78.00 to $70.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Finally, Citigroup initiated coverage on shares of Moderna in a research note on Thursday, March 13th. They issued a "neutral" rating and a $40.00 target price for the company. Four equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $46.61.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.